Diagnostic Accuracy of Anti-Mullerian Hormone for Polycystic Ovary Syndrome

Abstract

Objective: To determine the diagnostic accuracy of Anti-Mullerian Hormone in Polycystic ovary syndrome detection, keeping Rotterdam criteria as a gold standard.

Study Design: Cross-sectional study.

Place and Duration of Study: Armed Forces Institute of Pathology, Rawalpindi and Rehman Medical Institute, (RMI)Peshawar, Pakistan from Jul 2018 to Jun 2019.

Methodology: The study included one hundred and forty clinically suspected patients of polycystic ovary syndrome (PCOS) of 16-45 years of age. Blood samples were analyzed for serum Anti-Mullerian Hormone analysis on Architect ci 8200 System using the Chemiluminescent immunoassay technique. AMH was considered positive for Polycystic ovary syndrome at a threshold of 4.9ng/ml. In addition, AMH's diagnostic accuracy was evaluated, considering the Rotterdam criteria of PCOS as a gold standard.

Results: The mean age and mean BMI of the study subjects were 26.73±5.07 years and 30.43±4.83kg/m2, respectively. The mean follicle-stimulating and Luteinizing hormones were 4.34±0.68mIU/ml and 5.24±1.43mIU/ml, respectively. The mean Anti-Mullerian hormone of all patients was 7.79±4.62ng/ml. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the likelihood ratio of a positive test (LR+) and Likelihood ratio of a Negative Test (LR-) of AntiMullerian hormone were 91.8%, 74.7%, 73.7%, 92.2%, 3.63%, 0.11%, respectively and overall diagnostic accuracy was 82.1%.

Conclusion: Anti-Mullerian hormone can effectively determine the existence of Polycystic ovary syndrome among women of reproductive age and serve as a sensitive diagnostic tool for Polycystic ovary syndrome.